Cel Diabetic retinopathy (“DR”) is considered as a priority eye disease by the World Health Organisation, as one of the main causes of visual impairment. It is a complication of the eye that can affect anyone who has diabetes. Diabetic retinopathy causes damage to the blood vessels supplying the retina – the “seeing” part of the eye. Because retinopathy generally has no obvious symptoms until it is advanced, early detection is essential. Detection is made by retinal screening. This is a straightforward procedure which includes assessment of visual acuity and eye fundus photography. Then a medical specialist, who looks for signs of diabetic retinopathy, gives a grade allowing a further diagnosis. This makes the diagnosis heavily dependent on the image quality. iPRI, which current activity is based on consulting expertise in public health, has identified a need for delivering a practical solution to the DR diagnosis challenge. iPRI has created a new prototype of software to enhance the quality of colour eye fundus exams. Several tests on representative databases have shown to DR experts that there is an important medical interest to introduce this service in the diagnostic procedure. IPRI’s international network of Key Opinion Leaders in Diabetes has confirmed this interest. Through the EYE-LIGHT project, iPRI aims to integrate this proven technology into a medical device. It will be provided as a professional application software service in order to facilitate the DR diagnosis, improve the image quality, allow comparisons and make images sharable through telemedicine. In order to address the unmet medical need, iPRI has to scale up, industrialise and sell this medical device. Through the SME Instrument programme, iPRI intends to refine the business model of this new activity during phase 1, and to set up and clinically validate the medical device during phase 2. Dziedzina nauki engineering and technologymedical engineeringmedical and health scienceshealth sciencespublic healthmedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesclinical medicineophthalmologyretinopathy Słowa kluczowe Diabetic Retinopathy comparable and shareable eye fundus images images of better quality better diagnosis quality and colour image enhancement telemedicine e-health web-service Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Zaproszenie do składania wniosków H2020-SMEInst-2014-2015 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2015 System finansowania SME-1 - SME instrument phase 1 Koordynator IPRI SERVICES Wkład UE netto € 50 000,00 Adres 18 CHEMIN DES CUERS 69570 Dardilly Francja Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Auvergne-Rhône-Alpes Rhône-Alpes Rhône Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00